Mechanisms of Disease and Treatment in Novel Metabolic Developmental Brain Disorders

新型代谢性发育性脑疾病的疾病机制和治疗

基本信息

  • 批准号:
    10745757
  • 负责人:
  • 金额:
    $ 3.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-12-01 至 2026-11-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY We have recently identified a novel human neurogenetic disorder caused by loss-of-function mutations in the mitochondrial enzyme glutamate pyruvate transaminase 2 (GPT2). Genetic metabolic diseases, such as GPT2 disease, offer a powerful lens to investigate mechanisms of metabolism in human brain. Also, metabolic diseases may be amenable to treatments via dietary restrictions or supplements. GPT2 disease involves postnatal undergrowth of brain and progressive spastic paraplegia. Based on our extensive preliminary data, we have established potential treatment strategies for GPT2 disease. To guide these interventions in children, we propose to complete needed pre-clinical studies. GPT2 localizes to mitochondria and is upregulated during postnatal brain development. GPT2 catalyzes the reversible addition of an amino group from glutamate to pyruvate, yielding alanine and a-ketoglutarate, a metabolite in the tricarboxylic acid (TCA) cycle. Our preliminary data provide support for disease mechanisms, wherein GPT2 plays a critical role in neuronal growth by regulating neuronal alanine synthesis and anaplerosis. Anaplerosis (filling-up) is the metabolic process whereby TCA cycle intermediates are replenished. Anaplerosis is important during high biosynthetic demand, when TCA cycle intermediates are consumed for synthesis of macromolecules for cell growth, a process known as cataplerosis. Therefore, the central objective of this R01 application is to define the role of GPT2-mediated mechanisms in neuronal development and health, and to study the efficacy of mechanism- based treatments. Aim 1 is focused on in vivo studies of Gpt2-mediated growth of motor neurons. Our Gpt2- null mouse recapitulates key aspects of disease, such as hindlimb motor abnormalities, akin to spastic paraplegia seen in patients. In Aim1 and in Aim 2, we are developing mechanism-based rescue strategies to treat motor defects in vivo through metabolite supplementation in the diets of Gpt2-null animals. Aim 3 will define GPT2-mediated metabolic mechanisms governing neuronal growth and treatments in vitro. These studies are in both primary mouse neurons, as well as in human neurons (from stem cells) in order to translate advances back to the human context. We have a strong and multidisciplinary team permitting a powerful integrated translational approach, bridging patient-oriented studies to experimental models. In summary, research in this proposal will have a sustained impact on both fundamental neuroscience and treatment development. We will evaluate therapeutic strategies that could be rapidly implemented in patients with GPT2 disease, which currently has no known treatment. This progress would pave the way for early intervention, and potentially, prevention of neurologic damage in patients with GPT2 disease. Finally, these studies have broad significance, as we will define basic metabolic mechanisms required for growth and health of long-projecting neurons, including long-projecting motor neurons that are vulnerable in a variety of neurological diseases.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eric M Morrow其他文献

Postictal psychosis: presymptomatic risk factors and the need for further investigation of genetics and pharmacotherapy
  • DOI:
    10.1186/1744-859x-5-9
  • 发表时间:
    2006-07-21
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Eric M Morrow;Jennifer M Lafayette;Edward B Bromfield;Gregory Fricchione
  • 通讯作者:
    Gregory Fricchione

Eric M Morrow的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eric M Morrow', 18)}}的其他基金

Mechanisms of Disease and Treatments in Novel Metabolic Development Brain Disorders
新型代谢发育脑疾病的疾病机制和治疗
  • 批准号:
    10622084
  • 财政年份:
    2022
  • 资助金额:
    $ 3.26万
  • 项目类别:
Mechanisms of disease and treatment in novel metabolic developmental brain disorders
新型代谢性发育性脑疾病的疾病机制和治疗
  • 批准号:
    10375639
  • 财政年份:
    2021
  • 资助金额:
    $ 3.26万
  • 项目类别:
Mechanisms of Disease and Treatment in Novel Metabolic Developmental Brain Disorders
新型代谢性发育性脑疾病的疾病机制和治疗
  • 批准号:
    10527375
  • 财政年份:
    2021
  • 资助金额:
    $ 3.26万
  • 项目类别:
Mechanisms of disease and treatment in novel metabolic developmental brain disorders
新型代谢性发育性脑疾病的疾病机制和治疗
  • 批准号:
    10712302
  • 财政年份:
    2021
  • 资助金额:
    $ 3.26万
  • 项目类别:
Neurodegenerative mechanisms in Christianson syndrome and NHE6-related disorders
Christianson 综合征和 NHE6 相关疾病的神经退行性机制
  • 批准号:
    9811045
  • 财政年份:
    2019
  • 资助金额:
    $ 3.26万
  • 项目类别:
Neurodegenerative Mechanisms in Christianson Syndrome and NHE6-Related Disorders
Christianson 综合征和 NHE6 相关疾病的神经退行性机制
  • 批准号:
    10417212
  • 财政年份:
    2019
  • 资助金额:
    $ 3.26万
  • 项目类别:
Neurodegenerative mechanisms in Christianson syndrome and NHE6-related disorders
Christianson 综合征和 NHE6 相关疾病的神经退行性机制
  • 批准号:
    10020810
  • 财政年份:
    2019
  • 资助金额:
    $ 3.26万
  • 项目类别:
Neurodegenerative Mechanisms in Christianson Syndrome and NHE6-Related Disorders
Christianson 综合征和 NHE6 相关疾病的神经退行性机制
  • 批准号:
    10653694
  • 财政年份:
    2019
  • 资助金额:
    $ 3.26万
  • 项目类别:
Neurodegenerative Mechanisms in Christianson Syndrome and NHE6-Related Disorders
Christianson 综合征和 NHE6 相关疾病的神经退行性机制
  • 批准号:
    10213154
  • 财政年份:
    2019
  • 资助金额:
    $ 3.26万
  • 项目类别:
Neurodegenerative mechanisms in Christianson syndrome and NHE6-related disorders
Christianson 综合征和 NHE6 相关疾病的神经退行性机制
  • 批准号:
    10164658
  • 财政年份:
    2019
  • 资助金额:
    $ 3.26万
  • 项目类别:

相似海外基金

Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
  • 批准号:
    24K18114
  • 财政年份:
    2024
  • 资助金额:
    $ 3.26万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
  • 批准号:
    498288
  • 财政年份:
    2024
  • 资助金额:
    $ 3.26万
  • 项目类别:
    Operating Grants
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
  • 批准号:
    10089306
  • 财政年份:
    2024
  • 资助金额:
    $ 3.26万
  • 项目类别:
    Collaborative R&D
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
  • 批准号:
    23K20339
  • 财政年份:
    2024
  • 资助金额:
    $ 3.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
  • 批准号:
    498310
  • 财政年份:
    2024
  • 资助金额:
    $ 3.26万
  • 项目类别:
    Operating Grants
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
  • 批准号:
    2740736
  • 财政年份:
    2024
  • 资助金额:
    $ 3.26万
  • 项目类别:
    Studentship
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
  • 批准号:
    2406592
  • 财政年份:
    2024
  • 资助金额:
    $ 3.26万
  • 项目类别:
    Standard Grant
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
  • 批准号:
    2305890
  • 财政年份:
    2024
  • 资助金额:
    $ 3.26万
  • 项目类别:
    Fellowship Award
虚弱高齢者のSuccessful Agingを支える地域課題分析指標と手法の確立
建立区域问题分析指标和方法,支持体弱老年人成功老龄化
  • 批准号:
    23K20355
  • 财政年份:
    2024
  • 资助金额:
    $ 3.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
「ケア期間」に着目したbiological aging指標の開発
开发聚焦“护理期”的生物衰老指数
  • 批准号:
    23K24782
  • 财政年份:
    2024
  • 资助金额:
    $ 3.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了